Recurrent High Grade Glioma Treated by LITT
ConditionRecurrent High Grade Glioma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Tiantan Hospital
About this trial
This clinical trial aims to investigate the efficiency and safety of laser interstitial thermal therapy (LITT) in recurrent high-grade glioma (rHGG) patients.
The main questions it aims to answer are:
* The LITT would increase the progression-free survival and overall survival of rHGG patients compared to other treatments. * The LITT is safe and applicable to rHGG patients Participants will be randomized to the intervention group (LITT) or control group at a ratio of 2:1. The intervention group patients will receive LITT. The control group will be treated with any other treatment.
The primary outcome of this trial is progression-free survival. The estimated sample size is 135, 90 in the LITT group and 45 in the control group.
Eligibility criteria
Qualifiers
Aged 18 years old or above;
Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or 4 glioma and received standard treatment;
Meets the disease progression criteria in the Response Evaluation of Neuro-Oncology (RANO 2.0) criteria;
At least one image other than T1 contrast indicates progression;
Disqualifiers
Patients may benefit from other treatments or may not benefit from this trial;
No more than three months since the patient underwent craniotomy;
MRI contrast cannot be performed;
Severe coagulation disorder;
Trial design
Treatments tested in this trial
- LITT
- Control
Treatment groups
135 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov